[go: up one dir, main page]

CN1298301A - 用帕罗西汀治疗一般性焦虑症 - Google Patents

用帕罗西汀治疗一般性焦虑症 Download PDF

Info

Publication number
CN1298301A
CN1298301A CN99805328A CN99805328A CN1298301A CN 1298301 A CN1298301 A CN 1298301A CN 99805328 A CN99805328 A CN 99805328A CN 99805328 A CN99805328 A CN 99805328A CN 1298301 A CN1298301 A CN 1298301A
Authority
CN
China
Prior art keywords
paroxetine
treatment
solvate
pharmaceutically acceptable
general anxiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99805328A
Other languages
English (en)
Chinese (zh)
Inventor
R·扎尼内利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1298301A publication Critical patent/CN1298301A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN99805328A 1998-04-22 1999-04-22 用帕罗西汀治疗一般性焦虑症 Pending CN1298301A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808479.1A GB9808479D0 (en) 1998-04-22 1998-04-22 Method of treatment
GB9808479.1 1998-04-22

Publications (1)

Publication Number Publication Date
CN1298301A true CN1298301A (zh) 2001-06-06

Family

ID=10830715

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99805328A Pending CN1298301A (zh) 1998-04-22 1999-04-22 用帕罗西汀治疗一般性焦虑症

Country Status (20)

Country Link
EP (1) EP1073437A4 (pt)
JP (1) JP2002512189A (pt)
KR (1) KR20010034817A (pt)
CN (1) CN1298301A (pt)
AP (1) AP2000001959A0 (pt)
AU (1) AU3864899A (pt)
BG (1) BG104939A (pt)
BR (1) BR9909791A (pt)
CA (1) CA2328896A1 (pt)
CZ (1) CZ20003885A3 (pt)
EA (1) EA200001088A1 (pt)
GB (1) GB9808479D0 (pt)
HU (1) HUP0101350A3 (pt)
ID (1) ID27546A (pt)
IL (1) IL139167A0 (pt)
NO (1) NO20005286L (pt)
PL (1) PL343494A1 (pt)
SK (1) SK15672000A3 (pt)
TR (1) TR200003082T2 (pt)
WO (1) WO1999053919A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
TR200003082T2 (tr) 2001-01-22
AP2000001959A0 (en) 2000-12-31
KR20010034817A (ko) 2001-04-25
PL343494A1 (en) 2001-08-27
WO1999053919A1 (en) 1999-10-28
JP2002512189A (ja) 2002-04-23
HUP0101350A2 (hu) 2002-05-29
CA2328896A1 (en) 1999-10-28
BR9909791A (pt) 2000-12-26
ID27546A (id) 2001-04-12
HUP0101350A3 (en) 2002-06-28
CZ20003885A3 (cs) 2001-09-12
IL139167A0 (en) 2001-11-25
EP1073437A1 (en) 2001-02-07
NO20005286L (no) 2000-12-20
AU3864899A (en) 1999-11-08
EP1073437A4 (en) 2003-04-16
GB9808479D0 (en) 1998-06-17
SK15672000A3 (sk) 2001-04-09
NO20005286D0 (no) 2000-10-20
EA200001088A1 (ru) 2001-04-23
BG104939A (bg) 2001-09-28

Similar Documents

Publication Publication Date Title
US5371092A (en) Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
US4804669A (en) Treatment of pain with a piperidine
US6121291A (en) Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
AP460A (en) Naphthyl derivative for treatment method.
CN1263465A (zh) 利用选择性5－羟色胺再摄取抑制剂治疗和预防心脏病
US20020103250A1 (en) Method of treatment or prophylaxis
CN1298301A (zh) 用帕罗西汀治疗一般性焦虑症
CN1354662A (zh) 奥桑唐特在用于治疗心情疾病的药物制剂中的应用
US20040157910A1 (en) Method of treatment or prophylaxis
MXPA00010343A (en) Treatment of generalized anxiety disorder with paroxetine
WO1992008451A1 (en) Use of nabumetone for treatment of cancer pain
WO1992008452A1 (en) Use of nabumetone for the treatment of myofascial pain syndrome
MXPA00000522A (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (ssri)
IE913315A1 (en) Treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication